Reduction in BNP Levels With Treatment of Decompensated Heart Failure and Future Clinical Events

Amandeep S. Dhaliwal, Anita Deswal, Allison Pritchett, David Aguilar, Biswajit Kar, Julianne Souchek, Biykem Bozkurt

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

Background: Brain natriuretic peptide (BNP) levels correlate with outcomes in patients with heart failure (HF). We sought to compare the relationship between absolute and relative changes in BNP with future clinical events, and whether serial BNP measurements add prognostic information in patients treated for decompensated HF. Methods and Results: In 203 patients treated for HF, increasing tertiles of BNP levels after treatment had a hazard ratio of 1.4 (1.1-1.7, P < .01) and increasing tertiles of percent reduction in BNP, had a hazard ratio of 0.7 (0.6-0.9, P = .005), respectively, for the combined end point of total mortality or readmission for HF. Higher baseline BNP levels did not decrease to lower BNP levels as often as lower BNP levels (P < .001). Follow-up BNP performed better in a model, incorporating age, ejection fraction, prior HF hospitalization, New York Heart Association Class, race, use of β-blockers and renin-angiotensin axis inhibitors and renal insufficiency, than did baseline BNP or percent reduction in BNP. More BNP measurements other than the follow-up BNP did not improve the fit of the model further. Conclusions: These results suggest that both lower absolute BNP levels and greater percentage reduction in BNP with treatment of decompensated HF are associated with better event-free survival. Advocating a threshold BNP to which patients should be treated may not be possible given that high BNP levels tend not to decrease to levels associated with better outcomes during the short period of treatment. More BNP measurements do not add prognostic information beyond that provided by a single BNP level after treatment.

Original languageEnglish
Pages (from-to)293-299
Number of pages7
JournalJournal of Cardiac Failure
Volume15
Issue number4
DOIs
StatePublished - May 2009

Bibliographical note

Funding Information:
Dr. Bozkurt is a recipient of a Merit Entry Level grant support from Veterans Affairs Medical Research Service (MRS). Drs. Aguilar and Pritchett are recipients of Mentored Clinical Scientist Development Program (NIH- K12 Award) awards from NIH.

Keywords

  • biomarker
  • clinical outcomes
  • heart failure
  • Natriuretic peptides
  • serial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Reduction in BNP Levels With Treatment of Decompensated Heart Failure and Future Clinical Events'. Together they form a unique fingerprint.

Cite this